Seres Therapeutics: Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that it will present three related posters at the upcoming 2025 Digestive Disease Week (DDW) Conference being held May 3-6, 2025, in San Diego, CA.Seres previously reported exploratory translational biomarker data from its SER-155 Phase 1b study, which provided evidence supporting the intended therapeutic mechanisms. These included promoting intestinal epithelial barrier integrity to reduce the translocation of bacteria and inflammatory bacterial products into the bloodstream, as well as modulating systemic inflammatory responses. New results presented at the DDW conference could help identify candidate biomarkers to support the further clinical development of live biotherapeutics to treat inflammatory and immune diseases, including ulcerative colitis and Crohn's disease.Seres is currently seeking partnership opportunities to advance the development of its biotherapeutics in inflammatory and immune diseases.Presentation Details - New ResearchTitle: Characterization of IBD microbiomes in Models of Microbiome Disruption and Inflammation to Evaluate Candidate Biomarkers for Patient SelectionAbstract Number: Sa1770Presenter: Nicholas Beauchemin, Principal Scientist, R&DDate & Time: May 3, 2025 from 12:30 PM to ...Full story available on Benzinga.com